ANDA 91347, held by Teva Pharms. Vardenafil Hydrochloride.
As of Nov 16, 2026, ANDA 91347 (Vardenafil Hydrochloride), held by Teva Pharms, was first approved by FDA on May 3, 2012, with 4 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 3, 2012 | Original application | Approved | None posted |
| Vardenafil HydrochlorideEQ 2.5MG BASE · tablet;oral | Vardenafil Hydrochloride | Rx |
| Vardenafil HydrochlorideEQ 5MG BASE · tablet;oral | Vardenafil Hydrochloride | Rx |
| Vardenafil HydrochlorideEQ 10MG BASE · tablet;oral | Vardenafil Hydrochloride | Rx |
| Vardenafil HydrochlorideEQ 20MG BASE · tablet;oral | Vardenafil Hydrochloride | Rx |
| Aug 11, 2026 | Supplement 7Labeling · Standard review | Approved | None posted |
| Mar 7, 2023 | Supplement 4Labeling · Standard review | Approved | None posted |
| Dec 9, 2015 | Supplement 2Labeling · Standard review | Approved | None posted |
| Oct 30, 2012 | Supplement 1Labeling · Standard review | Approved | None posted |
| May 3, 2012 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters